Use of claims data for device problem tracking wins support in US regulatory and industry circles
This article was originally published in Clinica
Executive Summary
US Medicare claims data could be helpful as a post-marketing surveillance tool for high-risk devices, researchers at Dartmouth Medical School have concluded after using the data to determine possible risks associated with drug-eluting stents. The researchers were trying to determine whether Johnson & Johnson's Cypher stent posed a higher risk of sub-acute thrombosis, as the FDA had feared in the early months after release of the product.
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.